Evotec SE (FRA:EVT)
Germany
· Delayed Price · Currency is EUR | Market Cap | 988.40M |
| Revenue (ttm) | 756.33M |
| Net Income (ttm) | -158.98M |
| Shares Out | n/a |
| EPS (ttm) | -0.90 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 584,506 |
| Average Volume | 5,893 |
| Open | 5.57 |
| Previous Close | 5.51 |
| Day's Range | 5.47 - 5.67 |
| 52-Week Range | 5.07 - 9.30 |
| Beta | n/a |
| RSI | 44.20 |
| Earnings Date | Apr 20, 2026 |
About Evotec SE
Evotec SE operates as a drug discovery and development company in the United States, Germany, France, the United Kingdom, Switzerland, and internationally. It operates in two segments, Shared R&D and Just – Evotec Biologics. The company is developing pharmaceutical products in various therapeutic areas, such as oncology, autoimmune, cancer, diabetes, heart failure, immunology, pain and inflammation, infectious, kidney, liver, respiratory, fibrotic and metabolic disease, and rare diseases; central nervous system (CNS) and cardiometabolic disease... [Read more]
Financial Performance
In 2024, Evotec SE's revenue was 796.97 million, an increase of 1.99% compared to the previous year's 781.43 million. Losses were -196.08 million, 133.7% more than in 2023.
Financial StatementsNews
EQS-NVR: Evotec SE: Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
EQS Total Voting Rights Announcement: Evotec SE / Total Voting Rights Announcement Evotec SE: Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Euro...
EQS-PVR: Evotec SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
EQS Voting Rights Announcement: Evotec SE Evotec SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution 24.11.202...
EQS-DD: Evotec SE: Wesley Wheeler, buy
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them 13.11.2025 / 13:18 CET/CEST The issuer is solely responsi...
Evotec (EVO) Secures $5M Milestone from Bristol Myers Squibb
Evotec (EVO) Secures $5M Milestone from Bristol Myers Squibb
Evotec gets $5M milestone payment from Bristol Myers after FDA accepts new drug application
Evotec Receives Milestone Payment from Bristol Myers Squibb Following IND Acceptance in Strategic Protein Degradation Partnership
Milestone payment reflects continued progress under strategic research collaboration addressing high-need patient populations FDA clearance of IND application triggered a US$ 5 m milestone payment to ...
Evotec Hits Milestone with Bristol Myers Squibb in Protein Partnership
Evotec's partnership with Bristol Myers Squibb marks a pivotal step in advancing cancer therapies, with the FDA's nod on their IND application paving the way for groundbreaking clinical trials. Jetzt ...
Evotec SE 2025 Q3 - Results - Earnings Call Presentation
EQS-CMS: Evotec SE: Release of a capital market information
EQS Post-admission Duties announcement: Evotec SE / Announcement pursuant to Article 5(1)(a) of Regulation (EU) No. 596/2014 in conjunc-tion with Article 2(1) of Delegated Regulation (EU) No. 2016/105...
Evotec SE (EVOTF) Q3 2025 Earnings Call Highlights: Strategic Partnerships and Cost Reductions ...
Evotec SE (EVOTF) Q3 2025 Earnings Call Highlights: Strategic Partnerships and Cost Reductions Amid Revenue Challenges
Q3 2025 Evotec SE Earnings Call Transcript
Q3 2025 Evotec SE Earnings Call Transcript
Evotec SE (EVO) Q3 2025 Earnings Call Transcript
Evotec SE (EVO) Q3 2025 Earnings Call November 5, 2025 8:00 AM ESTCompany ParticipantsVolker Braun - Executive VP and Head of Global Investor Relations...
Earnings Scheduled For November 5, 2025
Companies Reporting Before The Bell • Avient (NYSE: AVNT) is estimated to report quarterly earnings at $0.69 per share on revenue of $821.57 million. • mF International (NASDAQ: MFI) is likely to re...
Evotec SE reports Q3 results
Evotec SE Reports 9M 2025 Results: Continued Strong Execution on Strategic Priorities
Group revenues of € 535.1 m ((7.1)%); Discovery & Preclinical Development segment ("D&PD", (12.3)%) still sees soft demand;Just - Evotec Biologics ("JEB"; +11.3%) above-expectation; further accelerati...
Evotec SE Reports 9M 2025 Results: Continued Strong Execution on Strategic Priorities
Group revenues of € 535.1 m ((7.1)%); Discovery & Preclinical Development segment ("D&PD", (12.3)%) still sees soft demand;Just - Evotec Biologics ("JEB"; +11.3%) above-expectation; further accelerati...
Evotec SE: Strong 9M 2025 Results with Strategic Focus
Evotec SE's financial journey reflects a blend of challenges and opportunities, with strategic partnerships and future-focused initiatives steering the company towards a promising trajectory. Jetzt de...
EQS-News: Evotec SE reports 9M 2025 results: Continued strong execution on strategic priorities
EQS-News: Evotec SE / Key word(s): 9 Month figures Evotec SE reports 9M 2025 results: Continued strong execution on strategic priorities 05.11.2025 / 07:30 CET/CEST The issuer is solely responsible fo...
Sandoz To Acquire Just-Evotec Biologics EU SAS In Strategic Biosimilars Expansion Deal
(RTTNews) - Sandoz (SDZNY) announced a strategic agreement with Evotec SE to acquire all issued and outstanding equity interests of Just-Evotec Biologics EU SAS (JEB SAS), including its Toulouse-based...
Evotec (EVO) Sells Biologics Site to Sandoz for $350M
Evotec (EVO) Sells Biologics Site to Sandoz for $350M
Evotec signs deal with Sandoz for Just - Evotec Biologics site
In A Landmark Industry Transaction, Evotec Signs Agreement With Sandoz, Resulting In Payments Potentially Over US $650 M Plus Royalties
Transaction showcases Evotec's unique capability enabling customers to produce biologics faster and at lower costs through its continuous manufacturing technologyAccelerated implementation of strategy...
In A Landmark Industry Transaction, Evotec Signs Agreement With Sandoz, Resulting In Payments Potentially Over US $650 M Plus Royalties
Transaction showcases Evotec's unique capability enabling customers to produce biologics faster and at lower costs through its continuous manufacturing technology Accelerated implementation of strateg...
Earnings To Watch: Evotec SE (EVO) Reports Q3 2025 Result
Earnings To Watch: Evotec SE (EVO) Reports Q3 2025 Result
Evotec SE to Announce Results for The First Nine Months 2025 on 05 November 2025
HAMBURG, DE / ACCESS Newswire / October 29, 2025 / Evotec SE (Frankfurt Stock Exchange: EVT, SDAX/TecDAX, Prime Standard, ISIN: DE0005664809, WKN 566480; NASDAQ:EVO) will announce its interim statemen...